Why the study?
COVID-19 can cause myocardial injury in the acute phase, but information regarding late cardiac consequences of the infection remains limited.
Does a history of COVID-19 infection result in long-term cardiac structural and functional abnormalities in survivors compared to healthy and risk-factor matched controls?
Does a history of COVID-19 infection result in long-term cardiac structural and functional abnormalities in survivors compared to healthy and risk-factor matched controls?
COVID-19 survivors, including those with severe illness or acute myocardial injury, do not show persistent echocardiographic or biomarker evidence of cardiac abnormalities nearly one year after recovery.
Answers are grounded in this paper and cite their sources.
No late cardiac abnormalities on echo or biomarkers in COVID-19 survivors; leaves open subclinical or prognostic effects beyond one year.
Background: Coronavirus disease 2019 can result in myocardial injury in the acute phase. However, information on the late cardiac consequences of coronavirus disease 2019 (COVID-19) is limited. Methods: We conducted a prospective observational cohort study to investigate the late cardiac consequences of COVID-19. Standard echocardiography and myocardial strain assessment were performed, and cardiac blood biomarkers were tested in 86 COVID-19 survivors 327 days (IQR 318–337 days) after recovery. Comparisons were made with 28 age-matched and sex-matched healthy controls and 30 risk factor-matched patients. Results: There were no significant differences in all echocardiographic structural and functional parameters, including left ventricular (LV) global longitudinal strain, right ventricular (RV) longitudinal strain, LV end-diastolic volume, RV dimension, and the ratio of peak early velocity in mitral inflow to peak early diastolic velocity in the septal mitral annulus (E/e') among COVID-19 survivors, healthy controls and risk factor-matched controls. Even 26 patients with myocardial injury at admission did not have any echocardiographic structural and functional abnormalities. There were no significant differences among the three groups with respect to serum concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (cTnI). Conclusion: This study showed that COVID-19 survivors, including those with myocardial injury at admission and those with severe and critical types of illness, do not have any echocardiographic evidence of cardiac structural and functional abnormalities 327 days after diagnosis.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: